Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

North China Pharmaceutical Group Gets Europe GMP Nod For Injectable

This article was originally published in PharmAsia News

Executive Summary

Huamin Co., a subsidiary of North China Pharmaceutical Group (NCPG), officially received a GMP certificate from the Medicines and Healthcare products Regulators Agency in the U.K., indicating its sterile powder for injection can be sold in the EU region.

You may also be interested in...



There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable

There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel